Melola Discovery

← Melola Discovery

Open access Journal SINTA 1

Mortality Comparison of Using Anti Interleukin-6 Therapy and Using Standard Treatment in Severe Covid-19

Folia Medica Indonesiana · Vol. 57 No. 2 (2021) · pp. 158–158

DOI
10.20473/fmi.v57i2.21929
ISSN
2355-8393, 2599-056X
Published
2021-06-01
Publisher
Airlangga University
Language
en
License
creativecommons.org/licenses/by-nc-sa/4.0/

Abstract

Severe Coronavirus Disease 19 (COVID-19) can cause serious lung inflammation and death. COVID-19 is characterized by a high mortality rate. This severity is associated with the overproduction of proinflammatory cytokines called "cytokine storms". One of the cytokines that play a central role is Interleukin-6 (IL-6). High IL-6 levels are associated with mortality. Expectedly, the IL-6 blockade could reduce cytokine storms and thus reduce deaths in severe COVID-19 patients. This systematic review aimed to summarize the comparison between mortality using anti-IL-6 therapy and mortality using standard treatment in severe COVID-19 patients. We systematically searched the PubMed, ScienceDirect, and ProQuest databases until 13 August 2020. After screening, twelve studies matched the inclusion criteria. The mortality of the anti-IL-6 therapy group was lower than the standard treatment group without anti-IL-6 therapy in COVID-19 patients in 10 of the 12 studies obtained. Four of the ten studies statistically found a significant difference in mortality of the anti-IL-6 therapy group and the standard treatment group. Confirmation of anti-IL-6 therapy effectiveness in reducing mortality in severe COVID-19 patients will require randomized controlled trials.

Keywords

Collaboration network of the authors

24 authors · 64 co-authorship links · 14 across different organisations

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Universitas Airlangga
  • Rumah Sakit Dokter Soetomo
  • University of Technology Malaysia
  • Universitas Pattimura
  • Mulawarman University
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Annette d’ArqomUniversitas Airlangga2
Mhd Zamal NasutionUniversitas Airlangga2
Sri PurwaningsihUniversitas Airlangga1
Yuani SetiawatiUniversitas Airlangga1
Farhan NurdiansyahUniversitas Airlangga1
Nurmawati FatimahUniversitas Airlangga1
Kusuma Eko PurwantariUniversitas Airlangga1
Qonita BajuberUniversitas Airlangga1
Edward KusumaUniversitas Airlangga1
Junaidah YusofUniversity of Technology Malaysia1
Kinesha KostyaUniversitas Airlangga1
Nazwa Febry SaviraUniversitas Airlangga1
Juen Carla WarellaUniversitas Pattimura1
Rebekah Juniati SetiabudiUniversitas Airlangga1
Khairunnida RahmaMulawarman University1
Ahmad Veri EriantoUniversitas Airlangga1
Tri Pudy AsmarawatiRumah Sakit Dokter Soetomo1
Brian Eka RachmanRumah Sakit Dokter Soetomo1
Budi SupraptiUniversitas Airlangga1
Muhammad Thariq NadhafiAffiliation unknown1
Bambang WahjuprajitnoAffiliation unknown1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, first harvested 19 Nov 2026, last seen 19 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Mortality Comparison of Using Anti Interleukin-6 Therapy and Using Standard Treatment in Severe Covid-19</dc:title><dc:creator>Jonathan Christianto Sutadji</dc:creator><dc:creator>Agung Dwi Wahyu Widodo</dc:creator><dc:creator>Danti Nur Indiastuti</dc:creator><dc:subject>severe COVID-19</dc:subject><dc:subject>interleukin-6</dc:subject><dc:subject>IL-6 inhibition</dc:subject><dc:subject>cytokine storm</dc:subject><dc:subject>mortality</dc:subject><dc:subject>standard treatment</dc:subject><dc:subject>inflammatory cytokines</dc:subject><dc:subject>lung inflammation</dc:subject><dc:description xml:lang="en">Severe Coronavirus Disease 19 (COVID-19) can cause serious lung inflammation and death. COVID-19 is characterized by a high mortality rate. This severity is associated with the overproduction of proinflammatory cytokines called "cytokine storms". One of the cytokines that play a central role is Interleukin-6 (IL-6). High IL-6 levels are associated with mortality. Expectedly, the IL-6 blockade could reduce cytokine storms and thus reduce deaths in severe COVID-19 patients. This systematic review aimed to summarize the comparison between mortality using anti-IL-6 therapy and mortality using standard treatment in severe COVID-19 patients. We systematically searched the PubMed, ScienceDirect, and ProQuest databases until 13 August 2020. After screening, twelve studies matched the inclusion criteria. The mortality of the anti-IL-6 therapy group was lower than the standard treatment group without anti-IL-6 therapy in COVID-19 patients in 10 of the 12 studies obtained. Four of the ten studies statistically found a significant difference in mortality of the anti-IL-6 therapy group and the standard treatment group. Confirmation of anti-IL-6 therapy effectiveness in reducing mortality in severe COVID-19 patients will require randomized controlled trials.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2021-06-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v57i2.21929</dc:identifier><dc:identifier>10.20473/fmi.v57i2.21929</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 57 No 2 (2021); 158-158</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/21929/14938</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>